Adaptive Biotechnologies Corp - 10-Q Filing
Adaptive Biotechnologies Corp reports Q3 2026 financial results featuring revenue from Sequencing, MRD, and Immune Medicine segments.
Tickers: $ADPT
Read the full article at SEC EDGAR
Part of the story Adaptive Biotechnologies Corp - 10-Q Filing (3 articles)